Daniel M Altmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3562140/publications.pdf

Version: 2024-02-01

131 papers	6,000 citations	38 h-index	98798 67 g-index
139	139	139	10143 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet, The, 2021, 397, 1057-1058.	13.7	360
2	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	12.6	286
3	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117.	27.8	280
4	Immune boosting by B.1.1.529 $\mbox{\sc k}\mbox{\sc k}\mbox{\sc k}\mbox{\sc cov-2}$ exposure. Science, 2022, 377, .	12.6	241
5	SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Science Immunology, 2020, 5, .	11.9	240
6	Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut, 2019, 68, 1430-1438.	12.1	235
7	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	6.0	198
8	Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression. Journal of Experimental Medicine, 2009, 206, 1535-1547.	8.5	192
9	What policy makers need to know about COVID-19 protective immunity. Lancet, The, 2020, 395, 1527-1529.	13.7	188
10	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, .	11.9	172
11	Immunity to SARS-CoV-2 variants of concern. Science, 2021, 371, 1103-1104.	12.6	169
12	Innate Immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor $1\ (NCR1)$. Journal of Neuroinflammation, 2012, 9, 1.	7.2	147
13	COVID-19 vaccination: The road ahead. Science, 2022, 375, 1127-1132.	12.6	134
14	Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infectious Diseases, The, 2015, 15, 840-851.	9.1	107
15	The Mechanism of Superantigen-Mediated Toxic Shock: Not a Simple Th1 Cytokine Storm. Journal of Immunology, 2005, 175, 6870-6877.	0.8	106
16	Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. Journal of Infection, 2021, 82, 399-406.	3.3	106
17	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
18	Progressive neurodegeneration following spinal cord injury. Neurology, 2018, 90, e1257-e1266.	1.1	97

#	Article	IF	CITATIONS
19	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	12.6	91
20	Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 523-554.	22.4	84
21	The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nature Reviews Immunology, 2021, 21, 762-768.	22.7	80
22	Antibiotic therapy and outcome from immune-checkpoint inhibitors., 2019, 7, 287.		77
23	High Incidence of Spontaneous Disease in an HLA-DR15 and TCR Transgenic Multiple Sclerosis Model. Journal of Immunology, 2005, 174, 1938-1946.	0.8	74
24	HLA-C and Killer Cell Immunoglobulin-like Receptor Genes in Idiopathic Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 327-333.	5.6	67
25	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy , 2021, 9, e003311.		66
26	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARSâ€'CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
27	Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood, 2005, 105, 2175-2179.	1.4	60
28	Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12964-12973.	7.1	59
29	Is selection for TCR affinity a factor in cytokine polarization?. Trends in Immunology, 2002, 23, 526-529.	6.8	58
30	A Nobel Prizeâ€worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology, 2018, 155, 283-284.	4.4	53
31	Risk of SARS-CoV-2 reinfection after natural infection. Lancet, The, 2021, 397, 1161-1163.	13.7	53
32	Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. European Journal of Immunology, 2004, 34, 1839-1848.	2.9	52
33	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
34	Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine, the, 2022, 10, 840-850.	10.7	52
35	HLA-DR Alleles in Amyloid \hat{l}^2 -Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele. Journal of Immunology, 2009, 183, 3522-3530.	0.8	48
36	Lung Defense through IL-8 Carries a Cost of Chronic Lung Remodeling and Impaired Function. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 557-571.	2.9	48

#	Article	IF	Citations
37	Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathologica, 2020, 140, 143-167.	7.7	48
38	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
39	Natural Exposure to Cutaneous Anthrax Gives Long-Lasting T Cell Immunity Encompassing Infection-Specific Epitopes. Journal of Immunology, 2010, 184, 3814-3821.	0.8	45
40	T Cell Immunity to the Alkyl Hydroperoxide Reductase of <i>Burkholderia pseudomallei</i> : A Correlate of Disease Outcome in Acute Melioidosis. Journal of Immunology, 2015, 194, 4814-4824.	0.8	44
41	Decoding the unknowns in long covid. BMJ, The, 2021, 372, n132.	6.0	44
42	Meningeal lymphatic vessels mediate neurotropic viral drainage from the central nervous system. Nature Neuroscience, 2022, 25, 577-587.	14.8	43
43	Infection with Burkholderia pseudomallei – immune correlates of survival in acute melioidosis. Scientific Reports, 2017, 7, 12143.	3.3	42
44	Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11749-11754.	7.1	40
45	Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C. Frontiers in Immunology, 2017, 8, 193.	4.8	40
46	Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 860-862.	2.9	37
47	Rapid synchronous type 1 IFN and virus-specific TÂcell responses characterize first wave non-severe SARS-CoV-2 infections. Cell Reports Medicine, 2022, 3, 100557.	6.5	36
48	Waning immunity to SARS-CoV-2: implications for vaccine booster strategies. Lancet Respiratory Medicine, the, 2021, 9, 1356-1358.	10.7	35
49	Biochemical characterization of the human diabetes-associated HLA-DQ8 allelic product: Similarity to the major histocompatibility complex class II I-Ag7 protein of non-obese diabetic mice. European Journal of Immunology, 1997, 27, 2478-2483.	2.9	32
50	Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response. Acta Neuropathologica, 2013, 126, 501-515.	7.7	32
51	The serodominant secreted effector protein of <i>Salmonella</i> , SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse <scp>HLA</scp> class <scp>II</scp> alleles. Immunology, 2014, 143, 438-446.	4.4	32
52	In Vivo Enhancement of Peptide Display by MHC Class II Molecules with Small Molecule Catalysts of Peptide Exchange. Journal of Immunology, 2009, 182, 6342-6352.	0.8	31
53	Non-obese diabetic mice hemizygous at the T cell receptor \hat{l}_{\pm} locus are susceptible to diabetes and sialitis. European Journal of Immunology, 1996, 26, 953-956.	2.9	28
54	Relapsing and remitting experimental allergic encephalomyelitis: A focused response to the encephalitogenic peptide rather than epitope spread. European Journal of Immunology, 1997, 27, 2927-2934.	2.9	28

#	Article	IF	CITATIONS
55	HLA-DQB1*0602 Determines Disease Susceptibility in a New "Humanized―Multiple Sclerosis Model in HLA-DR15 (DRB1*1501;DQB1*0602) Transgenic Mice. Journal of Immunology, 2009, 183, 3531-3541.	0.8	27
56	CD4+ T Cell Epitopes of FliC Conserved between Strains of <i>Burkholderia</i> : Implications for Vaccines against Melioidosis and Cepacia Complex in Cystic Fibrosis. Journal of Immunology, 2014, 193, 6041-6049.	0.8	27
57	Chronic Infection by Mucoid <i>Pseudomonas aeruginosa</i> Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1250-1264.	5.6	27
58	Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. International Immunology, 2005, 17, 1157-1165.	4.0	26
59	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. ELife, 2020, 9, .	6.0	26
60	Spread of T Lymphocyte Immune Responses to Myelin Epitopes With Duration of Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2005, 64, 371-377.	1.7	24
61	Increased <scp>HLA</scp> â€E expression in white matter lesions in multiple sclerosis. Immunology, 2012, 137, 317-325.	4.4	24
62	Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis. Neurology, 2014, 83, 1321-1325.	1.1	24
63	KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells. European Journal of Immunology, 2016, 46, 185-191.	2.9	23
64	A role of cellular prion protein in programming T ell cytokine responses in disease. FASEB Journal, 2009, 23, 1672-1684.	0.5	22
65	Exacerbated autoimmunity associated with a T helper-1 cytokine profile shift in H-2E-transgenic mice. European Journal of Immunology, 1995, 25, 3134-3141.	2.9	21
66	Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancet, The, 2021, 398, 2057-2059.	13.7	19
67	The cellular prion protein is preferentially expressed by CD4 ⁺ â€fCD25 ⁺ â€fFoxp3 ⁺ regulatory T cells. Immunology, 2008, 125, 313-319.	4.4	18
68	Anthrax Lethal Factor as an Immune Target in Humans and Transgenic Mice and the Impact of HLA Polymorphism on CD4+ T Cell Immunity. PLoS Pathogens, 2014, 10, e1004085.	4.7	18
69	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on TÂcell recognition. Cell Reports Medicine, 2021, 2, 100286.	6.5	18
70	HLAâ€DR polymorphism in SARSâ€CoVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77.	4.4	18
71	CD4 T Cells Selected by Antigen Under Th2 Polarizing Conditions Favor an Elongated TCRα Chain Complementarity-Determining Region 3. Journal of Immunology, 2002, 168, 1018-1027.	0.8	17
72	Repertoire of HLA-DR1-Restricted CD4 T-Cell Responses to Capsular Caf1 Antigen of <i>Yersinia pestis </i> in Human Leukocyte Antigen Transgenic Mice. Infection and Immunity, 2010, 78, 4356-4362.	2.2	17

#	Article	IF	CITATIONS
73	The case against epitope spread in experimental allergic encephalomyelitis. Immunological Reviews, 1998, 164, 101-110.	6.0	15
74	Immune Control of Burkholderia pseudomallei––Common, High-Frequency T-Cell Responses to a Broad Repertoire of Immunoprevalent Epitopes. Frontiers in Immunology, 2018, 9, 484.	4.8	15
75	Update: HLA-DQ Associations with Autoimmune Disease. Autoimmunity, 1993, 14, 79-83.	2.6	13
76	Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax, 2014, 69, 335-345.	5.6	13
77	Anthrax in injecting drug users: the need for increased vigilance in the clinic. Expert Review of Anti-Infective Therapy, 2015, 13, 681-684.	4.4	13
78	Guillain-Barré syndrome and arboviral infection in Brazil. Lancet Infectious Diseases, The, 2017, 17, 693-694.	9.1	13
79	Neuroimmunology and neuroinflammation in autoimmune, neurodegenerative and psychiatric disease. Immunology, 2018, 154, 167-168.	4.4	13
80	Pulmonary Infection with <i>Cryptococcus neoformans</i> in the Face of Underlying Sarcoidosis. Respiration, 2007, 74, 462-466.	2.6	12
81	Strong CD4 T Cell Responses to Zika Virus Antigens in a Cohort of Dengue Virus Immune Mothers of Congenital Zika Virus Syndrome Infants. Frontiers in Immunology, 2020, 11, 185.	4.8	12
82	Mouse mammary tumor virus-mediated T-cell receptor negative selection in HLA-DRA transgenic mice. Human Immunology, 1993, 37, 149-156.	2.4	11
83	An Epitope of Bacillus anthracis Protective Antigen That Is Cryptic in Rabbits May Be Immunodominant in Humans. Infection and Immunity, 2010, 78, 2353-2354.	2.2	11
84	Host immunity to <i>Bacillus anthracis</i> lethal factor and other immunogens: implications for vaccine design. Expert Review of Vaccines, 2015, 14, 429-434.	4.4	11
85	CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor. Frontiers in Microbiology, 2016, 6, 1506.	3.5	11
86	Review series on helminths, immune modulation and the hygiene hypothesis: Nematode coevolution with adaptive immunity, regulatory networks and the growth of inflammatory diseases. Immunology, 2009, 126, 1-2.	4.4	10
87	Injectional anthrax infection due to heroin use induces strong immunological memory. Journal of Infection, 2014, 68, 200-203.	3.3	10
88	Adaptive immunity to SARS-CoV-2. Oxford Open Immunology, 2020, 1, iqaa003.	2.8	10
89	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	12.6	10
90	Anthrax Lethal Toxin and the Induction of CD4 T Cell Immunity. Toxins, 2012, 4, 878-899.	3.4	9

#	Article	IF	CITATIONS
91	Whole genome protein microarrays for serum profiling of immunodominant antigens of Bacillus anthracis. Frontiers in Microbiology, 2015, 6, 747.	3.5	9
92	MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity. BMC Neurology, 2015, 15, 72.	1.8	9
93	The immune regulatory role of neutrophils. Immunology, 2019, 156, 215-216.	4.4	9
94	CD4 ⁺ Tâ€cell immunity to the <i>Burkholderia pseudomallei</i> ABC transporter LolC in melioidosis. European Journal of Immunology, 2011, 41, 107-115.	2.9	8
95	Immune regulation in idiopathic bronchiectasis. Annals of the New York Academy of Sciences, 2012, 1272, 68-72.	3.8	8
96	Bioluminescent Reporting of In Vivo IFN- \hat{l}^3 Immune Responses during Infection and Autoimmunity. Journal of Immunology, 2019, 202, 2502-2510.	0.8	8
97	Children and the return to school: how much should we worry about covid-19 and long covid?. BMJ, The, 2021, 372, n701.	6.0	8
98	Models of multiple sclerosis. Drug Discovery Today: Disease Models, 2004, 1, 405-410.	1.2	7
99	Charcot–Marie–Tooth disease associated with recurrent optic neuritis. Journal of Clinical Neuroscience, 2011, 18, 1422-1423.	1.5	7
100	Natural cutaneous anthrax infection, but not vaccination, induces a CD4+ T cell response involving diverse cytokines. Cell and Bioscience, 2015, 5, 20.	4.8	7
101	Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized―Multiple Sclerosis-like Disease. Journal of Biological Chemistry, 2015, 290, 15260-15278.	3.4	7
102	COVIDâ€19 vaccines: what do we know so far?. FEBS Journal, 2021, 288, 4996-5009.	4.7	7
103	BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis. Frontiers in Immunology, 2021, 12, 767359.	4.8	6
104	Regulatory T cells in acute and chronic human Chikungunya infection. Microbes and Infection, 2022, 24, 104927.	1.9	6
105	Phenotypical characterization of regulatory T cells in acute Zika infection. Cytokine, 2021, 146, 155651.	3.2	5
106	The Human Prion Protein Residue 129 Polymorphism Lies Within a Cluster of Epitopes for T Cell Recognition. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1059-1068.	1.7	4
107	Elongated TCR alpha chain CDR3 favors an altered CD4 cytokine profile. BMC Biology, 2014, 12, 32.	3.8	4
108	BIITE: A Tool to Determine HLA Class II Epitopes from T Cell ELISpot Data. PLoS Computational Biology, 2016, 12, e1004796.	3.2	4

#	Article	IF	Citations
109	Tâ€cell immunology of the lung: maintaining the balance between host defence and immune pathology. Immunology, 2019, 156, 1-2.	4.4	4
110	Multiplexed gene expression analysis of HLA class II-associated podoconiosis implicates chronic immune activation in its pathogenesis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 926-936.	1.8	4
111	Autoantigen cross-reactive environmental antigen can trigger multiple sclerosis-like disease. Journal of Neuroinflammation, 2015, 12, 91.	7.2	3
112	New tools for <scp>MHC</scp> research from machine learning and predictive algorithms to the tumour immunopeptidome. Immunology, 2018, 154, 329-330.	4.4	3
113	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq1 1 0	.784314 rg	gBT ³ Overlock
114	Developing vaccines to counter bioterrorist threats. Expert Review of Vaccines, 2005, 4, 275-279.	4.4	2
115	Regulation, FoxP3, Suppression and Immunity. Immunology, 2008, 123, 1-2.	4.4	2
116	Functions of adiposeâ€resident immune subsets and the impact on metabolic syndrome. Immunology, 2018, 155, 405-406.	4.4	2
117	Covid-19 caseload in the UKâ€"assessments and mitigations. BMJ, The, 2021, 375, n2843.	6.0	2
118	Narrating the natural history of live infection by SARS CoV-2 VOC in animal models. EBioMedicine, 2021, 74, 103704.	6.1	2
119	Vaccine efficacy and immune interference: co-administering COVID-19 and influenza vaccines. Lancet Respiratory Medicine,the, 2022, 10, 125-126.	10.7	2
120	Reciprocal conditioning: T cells as regulators of dendritic cell function. Immunology, 2003, 109, 473-475.	4.4	1
121	Antagonist peptide for the treatment of bacterial superantigen toxic shock in a clinical or biowarfare setting. Expert Opinion on Therapeutic Patents, 2005, 15, 741-743.	5.0	1
122	Comment on "Frequency of Epitope-Specific Naive CD4+ T Cells Correlates with Immunodominance in the Human Memory Repertoireâ€. Journal of Immunology, 2012, 188, 5205-5206.	0.8	1
123	Bioinformatics for immunologists. Immunology, 2018, 155, 1-2.	4.4	1
124	Regulatory Tâ€eells: receptors, repertoires and roles in disease. Immunology, 2018, 155, 153-154.	4.4	1
125	Knowns and unknowns of tissueâ€resident memory T cells. Immunology, 2019, 157, 1-2.	4.4	1
126	Natural killer cell transcriptional control, subsets, receptors and effector function. Immunology, 2019, 156, 109-110.	4.4	1

#	Article	IF	CITATIONS
127	Mapping innate and adaptive immune function in arbovirus infections. Immunology, 2018, 154, 1-2.	4.4	O
128	Establishing the new playbook for interactions among microbiota, bacterial metabolites, adaptive immunity, autoimmune disease and metabolic syndrome. Immunology, 2018, 154, 533-534.	4.4	0
129	â€Just 17 if you know what I mean' … but what do we really mean to say about Th17 immunity?. Immunology, 2019, 156, 297-298.	4.4	O
130	A new immunology forum for a new age of immunology. Oxford Open Immunology, 2020, 1, .	2.8	0
131	SARS-Cov-2 immune waning and reinfection in care-home settings. The Lancet Healthy Longevity, 2021, 2, e776-e777.	4.6	0